<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895671</url>
  </required_header>
  <id_info>
    <org_study_id>P16/23 PONAZA</org_study_id>
    <nct_id>NCT03895671</nct_id>
  </id_info>
  <brief_title>PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS</brief_title>
  <acronym>PONAZA</acronym>
  <official_title>OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS - PONAZA TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is strategy aiming to improve the survival of patients with chronic myelogenous
      leukemia in advanced phase and myeloid blast crisis.

      The basis of this strategy is to add the demethylating agent 5-Azacitidine to the tyrosine
      kinase inhibitor ponatinib and evaluate its activity in 2 cohorts of patients with either
      chronic myelogenous leukemia in advanced phase or myeloid blast crisis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the overall survival of patients with AP-CML (cohort A) and MBC-CML (cohort-B) treated with the combination ponatinib and 5-azacitidine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety of combination of ponatinib and 5-azacitidine</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the safety of combination ofponatinib and 5-azacitidine: number adverse events related to ponatinib assessed by CTCAE V4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of Complete Hematologic Response (CHR)</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the rate of CHR : number de patient in complete hematologic response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cytogenetic response</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the complete cytogenetic response by caryotype analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>molecular response</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the major molecular responseby BCR-ABL IS quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of reversion to chronic phase CML</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the rate of reversion to chronic phase CML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>1 year</time_frame>
    <description>To estimate the duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of event free survival</measure>
    <time_frame>1 year</time_frame>
    <description>To estimate the duration of event-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relationship between clinical efficacy and biological markers (mutations and methylation status</measure>
    <time_frame>1 year</time_frame>
    <description>To investigate the relationship between clinical efficacy and biological markers: mutations and methylation status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>allogenic transplant</measure>
    <time_frame>1 year</time_frame>
    <description>To estimate the rate of patients bridged to allogenic transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival after transplant</measure>
    <time_frame>1 year</time_frame>
    <description>To follow up event-free survival after transplant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE</condition>
  <condition>CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS</condition>
  <arm_group>
    <arm_group_label>AP-CML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with Philadelphia chromosome positive CML in accelerated phase is defined by the presence of 15-29% blasts in peripheral blood (PB) or bone marrow (BM), ≥ 20% basophils in PB or BM, ≥ 30% blasts plus promyelocytes (with blasts &lt;30%) in PB or BM, &lt;100 x109/L platelets unrelated to therapy, or by clonal cytogenetics evolution (i.e., the presence of cytogenetic abnormalities other than the Philadelphia chromosome);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBC-CML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with Philadelphia chromosome positive CML in myeloid blast crisis is defined by the presence of ≥ 30% blasts in the bone marrow and/or peripheral blood or the presence of extramedullary disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib</intervention_name>
    <description>Induction phase (first three cycles)
- ponatinib: 45 mg/day orally continuously
Following the results of disease evaluation after 3 cycles:
Cohort A: AP-CML If a CHR and complete cytogenetic response are obtained after 3 months, ponatinib will be decreased at 30mg/day. If CHR and/or CCyR are not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.
Cohort B: MBC-CML If a CHR is obtained during the induction phase, ponatinib daily dose will be reduced to 30 mg/day. If CHR is not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.
Maintenance therapy:
Ponatinib will be decreased to 30 mg/day. During maintenance therapy, If a major molecular response is reached, ponatinib will be decreased to 15mg/day</description>
    <arm_group_label>AP-CML</arm_group_label>
    <arm_group_label>MBC-CML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Induction phase (first three cycles), Following the results of disease evaluation after 3 cycles and Maintenance therapy:
- 5-azacitidine : 75 mg/m² subcutaneously day 1 to day 7, every 4 weeks
No dose modification of 5-Azacitidine is planned in both cohorts. Azacitidine may be stopped at 24 months in case of MR4 defined as 0.0032%&lt;MR4≤0.01%;</description>
    <arm_group_label>AP-CML</arm_group_label>
    <arm_group_label>MBC-CML</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient aged 18 years or more

          2. Signed informed consent

          3. Patient with Philadelphia chromosome positive CML in first blast crisis or first
             accelerated phase:

               -  AP-CML is defined by the presence of any of the following features:

                    -  15-29% blasts in peripheral blood (PB) or bone marrow (BM)

                    -  ≥ 20% basophils in PB

                    -  ≥ 30% blasts plus promyelocytes (with blasts &lt;30%) in PB or BM,

                    -  &lt;100 x10(9)/L platelets unrelated to therapy, or by clonal cytogenetics
                       evolution (i.e., the presence of cytogenetic abnormalities other than the
                       Philadelphia chromosome);

               -  MBC-CML is defined by the presence of ≥ 30% blasts in the bone marrow and/or
                  peripheral blood or the presence of extramedullary disease.

          4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2 or 3

          5. Have adequate renal function as defined by the following criterion: Serum creatinine ≤
             1.5 × upper limit of normal (ULN) for institution

          6. Have adequate hepatic function as defined by the following criteria:

               1. Total serum bilirubin ≤ 1.5 × ULN, unless due to Gilbert's syndrome or CML

               2. Alanine aminotransferase (ALT) ≤ 2.5 × ULN, or ≤ 5 × ULN if leukemic infiltration
                  of the liver is present

               3. Aspartate aminotransferase (AST) ≤ 2.5 × ULN, or ≤ 5 × ULN if leukemic
                  infiltration of the liver is present

          7. Have normal pancreatic status as defined by the following criterion: Serum lipase and
             amylase ≤ 1.5 × ULN

          8. Have normal QTcF interval on screening electrocardiogram (ECG) evaluation, defined as
             QTcF of ≤ 450 ms in males or ≤ 470 ms in females.

          9. Have a negative pregnancy test documented prior to enrollment (for females of
             childbearing potential).

         10. Agree to use an effective form of contraception with sexual partners throughout study
             participation (for female and male patients who are fertile).

         11. Have fully recovered (≤ grade 1, returned to baseline, or deemed irreversible) from
             the acute effects of prior cancer therapy before initiation of study drug

        Exclusion Criteria:

          1. Pregnant or lactating women,

          2. Participation in another clinical trial with any investigative drug within 30 days
             prior to study enrolment,

          3. Prior history of hematopoietic stem cell transplantation

          4. Cardiovascular disease:

               -  Stage II to IV congestive heart failure (CHF) as determined by the New York Heart
                  Association (NYHA) classification system for heart failure.

               -  Myocardial infarction within the previous 6 months

               -  Symptomatic cardiac arrhythmia requiring treatment

          5. Individuals with another active malignancy

          6. Patients at high risk or very high risk of arterio-veinous occlusive disease defined
             by European CVD score

          7. Previous treatment with azacitidine,

          8. Diagnosis of malignant disease within the previous 12 months (excluding base cell
             carcinoma, &quot;in-situ&quot; carcinoma of the cervix or breast or other local malignancy
             excised or irradiated with a high probability of cure)

          9. Known active viral infection with Human Immunodeficiency Virus (HIV) or Hepatitis type
             B or C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mélody FORT</last_name>
    <phone>+33139239776</phone>
    <email>mfort@ch-versailles.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laure Morisset</last_name>
    <phone>+33139239785</phone>
    <email>lmorisset@ch-versailles.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire D'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine LEBON</last_name>
      <phone>03 22 45 59 14</phone>
      <email>lebon.delphine@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier D'Avignon</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harcène ZERAZHI</last_name>
      <phone>04 32 75 93 30</phone>
      <email>Hzerazhi@ch-avignon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de La Cote Basque</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric BAUDUER</last_name>
      <phone>05 59 44 38 41</phone>
      <email>bauduer.frederic@neuf.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thorsten BRAUN</last_name>
      <phone>01 48 95 70 51</phone>
      <email>thorsten.braun@avc.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriel ETIENNE</last_name>
      <phone>05 24 07 19 16</phone>
      <email>g.etienne@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Caen-Normandie</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain CHANTEPIE</last_name>
      <phone>02 31 27 25 39</phone>
      <email>chantepie-s@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Metropole Savoie</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Matteo PICA</last_name>
      <phone>04 79 96 51 05</phone>
      <email>gian-matteo.pica@ch-chambery.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric HERMET</last_name>
      <phone>04 73 75 00 65</phone>
      <email>ehermet@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lydia ROY</last_name>
      <phone>01 49 81 20 57</phone>
      <email>lydia.roy@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Lorraine CHRETIEN</last_name>
      <phone>01 30 80 29 50</phone>
      <email>marie-lorraine.chretien@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane COURBY</last_name>
      <phone>04 76 76 57 12</phone>
      <email>scourby@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Bicetre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ali TURHAN</last_name>
      <phone>01 45 21 35 94</phone>
      <email>ali.turhan@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno QUESNEL</last_name>
      <phone>03 20 44 66 40</phone>
      <email>bruno.quesnel@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal TURLURE</last_name>
      <phone>05 55 05 80 39</phone>
      <email>pascal.turlure@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck NICOLINI</last_name>
      <phone>04 69 85 61 93</phone>
      <email>franck-emmanuel.nicolini@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Viviane DUBRUILLE</last_name>
      <phone>02 40 08 32 71</phone>
      <email>viviane.dubruille@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Madalina UZUNOV</last_name>
      <phone>01 42 16 28 20</phone>
      <email>madalina.uzunov@psl.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital St Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simona LAPUSAN</last_name>
      <phone>01 49 28 34 42</phone>
      <email>simona.lapusan@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital St Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel RAFFOUX</last_name>
      <phone>01 42 49 96 49</phone>
      <email>emmanuel.raffoux@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Perpignan</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabienne VACHERET</last_name>
      <phone>04 68 61 64 48</phone>
      <email>fabienne.vacheret@ch-perpignan.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie BALSAT</last_name>
      <phone>04 78 86 22 50</phone>
      <email>marie.balsat@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale CONY-MAKHOUL</last_name>
      <phone>04 50 63 64 31</phone>
      <email>pconymakhoul@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine ESCOFFRE- BARBE</last_name>
      <phone>02 99 28 42 32</phone>
      <email>martine.escoffre-barbe@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal LENAIN</last_name>
      <phone>04 78 86 22 50</phone>
      <email>pascal.lenain@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shanti NATARAJAN-AME</last_name>
      <phone>03 88 12 76 73</phone>
      <email>shanti.ame@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire Du Cancer Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanne TAVITIAN</last_name>
      <phone>05 31 15 63 04</phone>
      <email>tavitian.suzanne@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru de Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agnes GUERCI-BRESLER</last_name>
      <phone>03 83 15 33 50</phone>
      <email>a.guerci@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles</name>
      <address>
        <city>Versailles</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe ROUSSELOT</last_name>
      <phone>0139638622</phone>
      <email>phrousselot@ch-versailles.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intitut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane DE BOTTON</last_name>
      <phone>01 42 11 40 79</phone>
      <email>stephane.debotton@igr.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Versailles Hospital</investigator_affiliation>
    <investigator_full_name>Philippe ROUSSELOT</investigator_full_name>
    <investigator_title>Clinical coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

